Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 464 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IntACT Clear all
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

NCT02644460
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
Interventions
Abemaciclib
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 23, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646
View directory record Official record
Conditions
Brain Tumor
Interventions
abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

NCT06415019
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 23, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders

NCT02596698
View directory record Official record
Conditions
Depression, Bipolar Disorder, Bipolar Disorder Not Otherwise Specified, Unspecified Mood Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older

NCT04421014
View directory record Official record
Conditions
Metabolic Syndrome, Normal Cognition
Interventions
Ketone Ester drink, Placebo: isocaloric dextrose drink
Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

NCT03362411
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 23, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

NCT03466736
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
[18F]flutemetamol PET scan
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 23, 2026, 5:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction

NCT02700152
View directory record Official record
Conditions
Excess Abdominal Fat
Interventions
UltraShape
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chestnut Hill, Massachusetts • Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Neonatal Resuscitation With Intact Cord

NCT02231411
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
V-DCC, Delayed cord clamping, Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 31 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Aging Brain Structure and Memory in Response to Exercise

NCT03855475
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aerobic exercise, Stretching
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 23, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Visual Rehabilitation After Occipital Stroke

NCT04798924
View directory record Official record
Conditions
Stroke, Ischemic, Quadrantanopia, Vision Loss Partial, Visual Field Defect, Peripheral, Peripheral Visual Field Defect of Both Eyes, Peripheral Visual Field Defect, Hemianopsia, Hemianopia, Homonymous Hemianopia, Homonymous Hemianopsia, Visual Fields Hemianopsia, Occipital Lobe Infarct, Quadrantanopsia, Stroke Hemorrhagic
Interventions
Subacute Training in the intact field, Subacute Training in the blind field, Chronic Training in the blind field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

Predict Tooth Wear

NCT06681844
View directory record Official record
Conditions
Prediction of Tooth Wear
Interventions
Tooth Shape assessed using an intraoral scanner one after avulsion
Other
Lead sponsor
Hospices Civils de Lyon
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

NCT05837845
View directory record Official record
Conditions
PTSD
Interventions
MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Drug · Behavioral
Lead sponsor
Patricia Suppes
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Autonomic Cardiovascular Integrity in Persons With SCI

NCT01758692
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Not listed
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

NCT01393912
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma
Interventions
Crenolanib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Months to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

Continuous Wireless Ultrasound to Monitor Fetal Health

NCT07676474
View directory record Official record
Conditions
Pregnant Woman With Single Pregnancy, Ultrasound Fetal Medicine
Interventions
Wireless Ultrasound Device
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction

NCT01869738
View directory record Official record
Conditions
ST Elevation Myocardial Infarction
Interventions
MGuard Prime, (BMS/DES)
Device
Lead sponsor
InspireMD
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
New Haven, Connecticut • Tampa, Florida • Elk Grove Village, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 23, 2026, 5:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test

NCT06864338
View directory record Official record
Conditions
Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
Interventions
Not listed
Lead sponsor
Mainz Biomed
Industry
Eligibility
18 Years and older
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

NCT03807765
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Nivolumab, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 23, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord

NCT00280306
View directory record Official record
Conditions
Spinal Cord Compression
Interventions
No interventions
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

NCT02757755
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8), Placebo (for Cohort 10^9)
Biological
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 23, 2026, 5:50 AM EDT